ASLAN Pharmaceuticals initiates Phase 2b study of eblasakimab for atopic dermatitis

Newswires MT 2022

All news about ASLAN PHARMACEUTICALS LIMITED
Sales 2021

Net income 2021 -847M
-30.6M
-30.6M
Net debt 2021

PER 2021 ratio -2.42x
2021 performance
Capitalization 1,771 million
64.1M
64.0 million
capi. / Sales 2021
capi. / Sales 2022
# of employees 18
Floating 41.2%

Chart ASLAN PHARMACEUTICALS LIMITED
Duration :

Period :

ASLAN Pharmaceuticals Limited Technical Analysis Chart |  MarketScreener

Technical Analysis Trends ASLAN PHARMACEUTICALS LIMITED

Short term Middle term Long term
Tendencies Bearish Bearish Bearish

Evolution of the income statement

To sell

To buy

Medium consensus SURPASS
Number of analysts 4
Last closing price

$0.92

Average target price

$8.00

Average Spread / Target 769%

Comments are closed.